Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis.
Kathleen TymmsBelinda E ButcherTegan SmithGeoffrey Owen Littlejohnnull nullPublished in: European journal of rheumatology (2020)
Baseline ACPA positivity was associated with improved clinical response using CDAI outcome measure at 12 months for abatacept but not for TNFi therapies.